Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates are non-viral engineered cell-based therapies designed to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, lysosomal disorders and diabetes. The engineered cells are protected by Sigilon’s Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.
Company profile
Ticker
SGTX
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Sigilon Securities Corporation ...
IRS number
474005543
SGTX stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
21 Dec 22
10-Q
2022 Q3
Quarterly report
10 Nov 22
8-K
Sigilon Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
10 Nov 22
8-K
Regulation FD Disclosure
11 Oct 22
8-K
Departure of Directors or Certain Officers
26 Sep 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
8-K
Sigilon Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
4 Aug 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
23 Jun 22
8-K
Submission of Matters to a Vote of Security Holders
26 May 22
10-Q
2022 Q1
Quarterly report
12 May 22
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | |
|---|---|---|---|
| Revenue | |||
| Cost of revenue | |||
| Operating income | |||
| Operating margin | |||
| Net income | |||
| Net profit margin | |||
| Cash on hand | |||
| Change in cash | |||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 34.21 mm | 34.21 mm | 34.21 mm | 34.21 mm | 34.21 mm | 34.21 mm |
| Cash burn (monthly) | 569.00 k | 8.96 mm | 2.81 mm | 4.44 mm | 3.33 mm | 5.14 mm |
| Cash used (since last report) | 2.47 mm | 38.98 mm | 12.21 mm | 19.29 mm | 14.48 mm | 22.34 mm |
| Cash remaining | 31.73 mm | -4.78 mm | 21.99 mm | 14.91 mm | 19.73 mm | 11.87 mm |
| Runway (months of cash) | 55.8 | -0.5 | 7.8 | 3.4 | 5.9 | 2.3 |
Institutional ownership, Q3 2022
87.9% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 34 |
| Opened positions | 2 |
| Closed positions | 7 |
| Increased positions | 7 |
| Reduced positions | 11 |
| 13F shares | Current |
|---|---|
| Total value | 567.23 mm |
| Total shares | 28.53 mm |
| Total puts | 0.00 |
| Total calls | 14.00 k |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Flagship Pioneering | 10.37 mm | $5.19 mm |
| Flagship Ventures Fund V | 8.89 mm | $426.93 mm |
| LLY Lilly(Eli) & Co | 2.74 mm | $131.82 mm |
| Canada Pension Plan Investment Board | 1.49 mm | $750.00 k |
| FMR | 1.06 mm | $537.00 k |
| BLK Blackrock | 1.06 mm | $535.00 k |
| Harbourvest Partners | 740.74 k | $374.00 k |
| State Of Wisconsin Investment Board | 509.63 k | $257.00 k |
| Vanguard | 300.91 k | $152.00 k |
| Artal | 276.00 k | $139.00 k |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 26 May 22 | Eric D. Shaff | Stock Option Common Stock | Grant | Acquire A | No | No | 0.7632 | 8,888 | 6.78 k | 8,888 |
| 26 May 22 | Oesterle Stephen N. | Stock Option Common Stock | Grant | Acquire A | No | No | 0.7632 | 8,888 | 6.78 k | 8,888 |
| 26 May 22 | Robert R Ruffolo | Stock Option Common Stock | Grant | Acquire A | No | No | 0.7632 | 8,888 | 6.78 k | 8,888 |
| 26 May 22 | Kavita Patel | Stock Option Common Stock | Grant | Acquire A | No | No | 0.7632 | 8,888 | 6.78 k | 8,888 |
| 26 May 22 | Cole Douglas G. | Stock Option Common Stock | Grant | Acquire A | No | No | 0.7632 | 8,888 | 6.78 k | 8,888 |
News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
19 Jan 23
Why Starbox Group Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
19 Jan 23
S&P 500 Down Over 1%; Bit Brother Shares Plummet
18 Jan 23
Why Ontrak Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
18 Jan 23
12 Health Care Stocks Moving In Wednesday's Intraday Session
18 Jan 23